Policy
-
A New Type of Drug ApprovalAt the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
-
Policy Matters
Forcing Big Tobacco to Tell the TruthA judge orders tobacco companies to come clean about the dangers of their products after decades of deception.
by Roy S. Herbst, MD, PhD
-
Forward Look
Tobacco Ads Admit Cigarettes Cause CancerCBS, ABC and NBC are airing advertisements that acknowledge the link between cigarettes and cancer.
by Sue Rochman
-
Forward Look
Tobacco’s Global ReachAction on Smoking and Health works to reduce global tobacco use.
by Sue Rochman
-
Policy Matters
Keep Safeguards That Protect Americans With CancerProtections contained in the Affordable Care Act that benefit cancer patients and survivors shoulds be preserved in any effort to replace or repeal the act.
by Gilbert S. Omenn, MD, PhD
-
The Cost of TreatmentAs efforts to change or repeal the Affordable Care Act continue, health care bills keep piling up for many cancer patients and caregivers.
by Sue Rochman
-
Forward Look
Your Tax Dollars at WorkQ&A with Joseph Unger on publicly funded cancer research.
by Sue Rochman
-
Cancer Control in the CommunitySuccessful public health initiatives to prevent, detect and treat cancer require widespread community participation.
by Marci A. Landsmann
-
Forward Look
Scientists Take a StandThousands of attendees who gathered at the Opening Ceremony of the American Association for Cancer Research (AACR) Annual Meeting 2017 sent a message on April 2 that cuts proposed by the Trump administration to the National Institutes of Health (NIH) budget would be devastating to cancer research, stall progress and ultimately harm cancer patients. The Annual […]
by Sue Rochman
-
A New Look for Clinical TrialsMore focused efforts aim to increase the number and type of participants in research studies. One goal is for study participants to be more like the patients who will take the drug if it is approved.
by Sue Rochman
